

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Studies evaluating brentuximab vedotin reported an overall response rate of 75% or higher for patients with _____.
 - a. Hodgkin lymphoma
 - b. Systemic anaplastic large T-cell lymphoma
 - c. Both a and b
2. The CALGB-50401 study demonstrated a higher overall response rate and longer event-free survival with lenalidomide and _____ compared to lenalidomide alone for patients with rituximab-refractory FL.
 - a. Rituximab
 - b. Bortezomib
 - c. Obinutuzumab
3. The SWOG-S0016 study evaluating R-CHOP versus CHOP with RIT for patients with newly diagnosed FL reported a significant difference in overall response rate and survival for patients receiving CHOP/RIT.
 - a. True
 - b. False
4. In a Phase I/II trial by Richardson and colleagues, the administration of MLN9708 in combination with lenalidomide and dexamethasone produced a response rate of 100% among evaluable patients.
 - a. True
 - b. False
5. A Phase II study evaluating 2 different doses of elotuzumab with lenalidomide/dexamethasone for patients with relapsed or refractory MM reported an overall response rate of 92% for patients who received lenalidomide/dexamethasone and elotuzumab 10 mg/kg.
 - a. True
 - b. False
6. The Phase III ASPIRE trial is evaluating _____ versus lenalidomide and dexamethasone for patients with relapsed MM.
 - a. CRd
 - b. RVD
 - c. Both of the above
7. The Phase III COMFORT-I and COMFORT-II trials of ruxolitinib versus placebo and ruxolitinib versus best available therapy for patients with myelofibrosis demonstrated statistically significant and sustained reduction in spleen size in patients on the ruxolitinib study arms.
 - a. True
 - b. False
8. Common side effects associated with nilotinib include which of the following?
 - a. Headache
 - b. Skin rash
 - c. Both a and b
 - d. Neither a nor b
9. The updated results of the Phase III StiL NHL1 trial demonstrated that the BR regimen was statistically superior to R-CHOP in terms of _____ for patients with indolent and mantle-cell lymphomas.
 - a. Overall survival
 - b. Progression-free survival
 - c. Both a and b
10. The ongoing Phase II/III MAINTAIN trial will evaluate 2 years versus _____ of maintenance therapy with rituximab after BR induction therapy for patients with non-Hodgkin lymphoma.
 - a. Eight years
 - b. Four years
 - c. One year